Sign inJoin waitlistJoin the waitlist

Carey Kernodle Anders

Chief, Division of Medical Oncology · Duke Department of Medicine

Credentials: ·

History

Division of Medical Oncology · Duke Department of Medicine
Present
Duke Department of Medicine
Present

Research

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
New England Journal of Medicine · 2020 · 1,022 citations
Brain metastases
Review · Nature Reviews Disease Primers · 2019 · 877 citations
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
Journal of Clinical Oncology · 2008 · First of 13 authors · Corresponding · 659 citations

Lisa Carey
39 papers
Nancy Lin
19 papers
SS
Sarah Sammons
18 papers
Elizabeth Dees
12 papers
KB
Kimberly Blackwell
12 papers
Peter Fecci
12 papers · 7 as a fellow
Eric Winer
11 papers
Hyman Muss
10 papers
IK
Ian Krop
10 papers
Matthew Ewend
10 papers
TZ
Timothy Zagar
10 papers
Laura Alder
8 papers

Grants

PARP Inhibition to Treat Triple-Negative Breast Cancer Brain Metastases
National Cancer Institute · K23
Contact PI · $867.4K · Univ of North Carolina Chapel Hill
2011–2016

Clinical trials

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Principal investigator · Active not recruiting · Phase 2
Carey Anders, M.D.
2023–2027
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Principal investigator · Completed · Phase 2
UNC Lineberger Comprehensive Cancer Center
2011–2017
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Site PI · Recruiting · Phase 1, Phase 2
Incyclix Bio
2023–2027